Double‐blind trial of triazolam 0.5 mg vs. nitrazepam 5 mg in outpatients

In a double-blind, cross-over trial, triazolam (0.5 mg) was compared with nitrazepam (5 mg) in patients with disturbed sleep. Each drug was given once, with a 48-h interval, to 40 outpatients. Quality, duration, and latency of sleep, and number of awakenings during the night, showed a significant difference in favour of triazolam. An overall evaluation of sleep also showed triazolam to be superior to nitrazepam. Both drugs seemed to reduce dream activity and to alter the character of the dreams. There was no significant difference in side effects.